Lindus Health, a London-based startup, just bagged $55 million in its latest funding round. Backed by big names like Peter Thiel, the company is on a mission to overhaul the often slow and clunky clinical trial process.

Clinical trials are crucial for getting new medicines and treatments to the public, but they’re notoriously time-consuming. From designing the trial to recruiting participants and collecting data, the whole process can take years. Lindus Health is stepping in to shake things up with its innovative platform, which uses automation and machine learning to streamline these steps.

The company calls itself the “anti-CRO” (contract research organization), offering an end-to-end solution that covers everything from protocol design to patient enrollment. Tools like their AI-powered protocol generator cut down on the labor-intensive parts of setting up trials, saving valuable time.

Lindus Health isn’t just about software, though. The startup also provides the medical staff needed to run trials, ensuring the process is smooth from start to finish. So far, they’ve worked with over 35,000 patients across Europe and the U.S., focusing on conditions like asthma, diabetes, and chronic fatigue syndrome.

The funding comes as AI continues to make waves in healthcare, particularly in drug discovery. With faster, more efficient trials, Lindus Health hopes to remove a major bottleneck in bringing new treatments to market.

The fresh $55 million will help the company expand its operations, including moving its global headquarters to the U.S. and investing in more advanced trial types and AI tools. “We’re just scratching the surface of what we can do with AI,” said co-founder Meri Beckwith.

With its innovative approach, Lindus Health is poised to make a big impact in the world of healthcare and beyond.